FDA Class II Recall: RemedyRepack's Potassium Chloride Capsules Fail Dissolution Specifications
RemedyRepack Inc. has initiated a Class II recall for Potassium Chloride Micro 10mEq K Extended Release Capsules due to critical dissolution failures, indicating CGMP deviations. This nationwide recall, impacting 142 blister cards, highlights significant quality control lapses in repackaging operations, demanding immediate review of supplier qualification and quality assurance protocols by procurement and regulatory teams.
FDA Identifies Critical Dissolution Failure in Potassium Chloride Repackaged by RemedyRepack
RemedyRepack Inc., based in Indiana, PA, has initiated a voluntary Class II recall, designated D-0611-2024, for specific lots of its Potassium Chloride Micro 10mEq K (750 mg) Extended Release Capsules. The primary reason cited for this significant market action is a failure to meet dissolution specifications, which points directly to Current Good Manufacturing Practice (CGMP) deviations within RemedyRepack's operations. This means the capsules are not releasing the active pharmaceutical ingredient, Potassium Chloride, at the rate or extent required, potentially compromising therapeutic efficacy and patient safety. For procurement directors, this event underscores the absolute necessity of rigorous quality control and robust supplier qualification processes for all third-party service providers, including repackagers. A dissolution failure in an extended-release product can lead to sub-therapeutic dosing or, conversely, dose dumping, both of which pose serious health risks. Regulatory affairs heads must recognize that such fundamental quality failures, even in repackaging, are critical indicators of systemic compliance issues that warrant immediate and comprehensive corrective actions, impacting the firm's overall regulatory standing.
RemedyRepack's Role and the Specifics of the Affected Potassium Chloride Product
RemedyRepack Inc., operating from Indiana, PA 15701, functioned as the repackager for the affected Potassium Chloride Micro 10mEq K (750 mg) Extended Release Capsules. The original manufacturer of the drug product was Glenmark, located in Mahwah, NJ 07430. The recalled product is packaged in 30-count blister cards, is Rx only, and carries the National Drug Code (NDC) 70518-1203-03. Two specific lots are implicated in this recall: J0758674-021824, with an expiration date of March 31, 2025, and J0751898-011424, expiring on January 31, 2025. This detail is crucial for supply chain VPs, as it allows for precise inventory identification and quarantine. The involvement of both an original manufacturer and a repackager highlights the complexities of pharmaceutical supply chains and the shared responsibility for product quality. Business development executives should note that quality issues at any point in the supply chain can damage brand reputation and erode market trust, irrespective of where the initial manufacturing occurred. Procurement teams must ensure that their quality agreements with repackaging partners clearly delineate responsibilities and establish stringent quality metrics, including dissolution testing for extended-release products.
Nationwide Distribution and Commercial Implications of the Potassium Chloride Recall
The recall of Potassium Chloride Micro 10mEq K Extended Release Capsules affects a total of 142 blister cards, each containing 30 capsules, resulting in 4,260 individual capsules being subject to the recall. This quantity, while not massive, was distributed USA Nationwide, indicating a broad market exposure for this quality lapse. The recall was initiated by RemedyRepack Inc. on June 26, 2024, and was subsequently terminated on January 31, 2025. For supply chain VPs, a nationwide distribution pattern amplifies the logistical challenges and costs associated with retrieving affected product from various points of sale and healthcare facilities. Procurement directors must account for the financial burden of managing such a recall, including reverse logistics, communication with distributors and customers, and potential replacement product sourcing. Furthermore, the disruption in the supply of an essential electrolyte replacement like Potassium Chloride can have broader implications for patient care and may lead to temporary shortages, creating opportunities for alternative suppliers who can demonstrate robust quality systems and reliable supply. Business development teams should monitor market reactions and competitor responses to assess potential shifts in market share.
Regulatory Risk Profile: Class II Recall and CGMP Compliance Implications for Repackagers
The FDA classified this event as a Class II recall, which signifies that the use of or exposure to the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. However, the underlying cause—CGMP deviations leading to out-of-specification dissolution—is a serious regulatory concern. For regulatory affairs heads, a Class II recall due to CGMP non-compliance is a clear signal that the FDA is actively monitoring the quality of repackaged drug products. While RemedyRepack is identified as a manufacturer in our knowledge graph, its specific role here as a repackager means it bears full responsibility for ensuring the quality and compliance of the repackaged product. This event serves as a critical reminder that all entities in the pharmaceutical supply chain, including those performing secondary operations like repackaging, must adhere strictly to CGMP regulations. Failure to do so not only triggers recalls but can also lead to more severe regulatory actions, such as Warning Letters, consent decrees, or even facility shutdowns, impacting future business operations and market access. Companies must proactively audit their repackaging partners to prevent similar compliance breaches.
Remediation Timeline and Future Outlook for RemedyRepack's Operations
The recall initiated by RemedyRepack Inc. on June 26, 2024, for Potassium Chloride Micro 10mEq K Extended Release Capsules, was officially terminated on January 31, 2025. A recall termination typically indicates that the FDA is satisfied that the firm has completed all reasonable efforts to remove or correct the product from the market. However, for senior decision-makers, this termination does not signify an end to scrutiny. Regulatory affairs heads should anticipate that the FDA will maintain a heightened level of oversight on RemedyRepack’s operations, potentially leading to future inspections focused on their quality systems and CGMP compliance, particularly concerning dissolution testing and repackaging controls. Procurement directors and supply chain VPs engaging with RemedyRepack, or any similar repackaging service, must conduct thorough post-recall audits to verify the effectiveness of the corrective and preventive actions (CAPA) implemented by the firm. This incident highlights the need for continuous vigilance and robust quality management systems to prevent recurrence of such critical quality failures, which can severely impact product availability, patient trust, and ultimately, commercial viability in the highly regulated pharmaceutical sector. Proactive engagement with suppliers on CAPA effectiveness is paramount.